Lilly’s immune modulator ixekizumab (Taltz) has received FDA approval for the treatment of moderate-to-severe plaque psoriasis in adults. Ixekizumab binds to interleukin 17-A to block inflammation, which is a hallmark of plaque psoriasis. The approval is based on three randomized, placebo-controlled clinical trials that showed Taltz achieved greater clinical response than placebo, with skin that was clear or almost clear, in plaque psoriasis patients who were candidates for systemic or phototherapy.

Click here for more.